{'52WeekChange': 0.82642305,
 'SandP52WeekChange': None,
 'address1': '9704 Medical Center Drive',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.93,
 'askSize': 1000,
 'averageDailyVolume10Day': 364350,
 'averageVolume': 3235573,
 'averageVolume10days': 364350,
 'beta': 2.816806,
 'beta3Year': None,
 'bid': 24.69,
 'bidSize': 3100,
 'bookValue': 3.879,
 'category': None,
 'circulatingSupply': None,
 'city': 'Rockville',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 25.96,
 'dayLow': 24.6238,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.915,
 'enterpriseToRevenue': 16.654,
 'enterpriseValue': 1135951104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '301 251 5321',
 'fiftyDayAverage': 26.502285,
 'fiftyTwoWeekHigh': 32.18,
 'fiftyTwoWeekLow': 4.04,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 47479118,
 'forwardEps': -2.17,
 'forwardPE': -11.6405525,
 'fromCurrency': None,
 'fullTimeEmployees': 384,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.074200004,
 'heldPercentInstitutions': 0.94183,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/macrogenics.com',
 'longBusinessSummary': 'MacroGenics, Inc., a biopharmaceutical company, '
                        'discovers and develops antibody-based therapeutics '
                        'for the treatment of cancer in the United States. Its '
                        'pipeline of immuno-oncology product candidates '
                        'includes Margetuximab, a monoclonal antibody, which '
                        'is in Phase III clinical trial that targets '
                        'HER2-expressing tumors, such as various breast and '
                        'gastroesophageal cancers. The company is also '
                        'developing Flotetuzumab, a DART molecule that '
                        'recognizes CD123 and CD3 for treating acute myeloid '
                        'leukemia; MGA012, an investigational monoclonal '
                        'antibody targeting PD-1; MGD013, a monoclonal '
                        'antibody that targets the PD-1 and '
                        'lymphocyte-activation gene 3; MGD019, a monoclonal '
                        'antibody that targets the immune checkpoints PD-1 and '
                        'cytotoxic T-lymphocyte-associated protein 4; and '
                        'Enoblituzumab, a monoclonal antibody that targets '
                        'B7-H3. In addition, the company is developing '
                        'combination of MGD009 and MGA012; MGC018, an antibody '
                        'drug conjugate, which targets solid tumors expressing '
                        'B7-H3; and MGD014, a DART molecule that targets '
                        'envelope protein of human immunodeficiency virus '
                        'infected cells and T cells. It has strategic '
                        'collaborations with Incyte Corporation; Zai Lab '
                        'Limited; and I-Mab Biopharma. MacroGenics, Inc. was '
                        'founded in 2000 and is headquartered in Rockville, '
                        'Maryland.',
 'longName': 'MacroGenics, Inc.',
 'market': 'us_market',
 'marketCap': 1241225856,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_600911',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -151518000,
 'nextFiscalYearEnd': 1640908800,
 'open': 25.48,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.03,
 'phone': '301 251 5172',
 'previousClose': 25.99,
 'priceHint': 2,
 'priceToBook': 6.5119877,
 'priceToSalesTrailing12Months': 18.197659,
 'profitMargins': -2.22141,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 25.96,
 'regularMarketDayLow': 24.6238,
 'regularMarketOpen': 25.48,
 'regularMarketPreviousClose': 25.99,
 'regularMarketPrice': 25.48,
 'regularMarketVolume': 444015,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 49131200,
 'sharesPercentSharesOut': 0.095,
 'sharesShort': 4665699,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4334852,
 'shortName': 'MacroGenics, Inc.',
 'shortPercentOfFloat': 0.1121,
 'shortRatio': 3.65,
 'startDate': None,
 'state': 'MD',
 'strikePrice': None,
 'symbol': 'MGNX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.096,
 'twoHundredDayAverage': 15.175108,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '322da638-92af-3f5e-9fb0-7915224804a7',
 'volume': 444015,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.macrogenics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '20850'}